IDEAYA Biosciences posts new investor presentation

IDEAYA Biosciences, Inc. filed a current report to note that it has posted an updated corporate presentation to the investor section of its website and furnished the same presentation as Exhibit 99.1.

Rhea-AI Filing Summary

IDEAYA Biosciences, Inc. filed a current report to note that it has posted an updated corporate presentation to the investor section of its website and furnished the same presentation as Exhibit 99.1. The presentation is dated January 12, 2026 and is intended to provide summary information about the company.

The company states that this information is being furnished under a disclosure item for investor presentations, not filed, so it is not subject to certain liability provisions of the securities laws and will not be automatically incorporated into other SEC filings. The presentation includes a Safe Harbor Statement addressing forward-looking statements.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IDEAYA Biosciences (IDYA) report in this 8-K filing?

IDEAYA Biosciences reported that it posted a corporate investor presentation on its website and furnished that presentation as Exhibit 99.1.

Where can investors find the new IDEAYA Biosciences investor presentation?

The company states that the corporate presentation was posted to the investor section of its website at https://ir.ideayabio.com/ and is attached as Exhibit 99.1.

Is the IDEAYA Biosciences investor presentation considered filed with the SEC?

The company specifies that the information under Item 7.01 and in Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act.

Will the IDEAYA Biosciences presentation be incorporated into other SEC filings?

The company states that the information in Item 7.01 and Exhibit 99.1 shall not be incorporated by reference into any other SEC filing, regardless of general incorporation language.

Does the IDEAYA Biosciences presentation include forward-looking statements?

Yes. The company refers readers to a slide titled “Safe Harbor Statement” in Exhibit 99.1 for important information about forward-looking statements.

What is the date of the IDEAYA Biosciences corporate presentation attached to the 8-K?

The filing identifies the company presentation attached as Exhibit 99.1 as being dated January 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 06:05 AM Learn about SEC filing dates

false 0001676725 0001676725 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

IDEAYA Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38915		47-4268251
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

5000 Shoreline Court, Suite 300

South San Francisco, California 94080

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 443-6209

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		IDYA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, IDEAYA Biosciences, Inc. (the “Company”) provided posted a corporate presentation to the investor section of the Company’s website at: https://ir.ideayabio.com/. The Company’s corporate presentation is attached hereto as Exhibit 99.1.

The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the slide titled “Safe Harbor Statement” in Exhibit 99.1 attached hereto.

The information furnished under this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section or Sections 11 or 12(a)(2) of the Securities Act. The information contained in this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Company presentation dated January 12, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IDEAYA BIOSCIENCES, INC.
Date: January 12, 2026				By:		/s/ Yujiro Hata
						Yujiro Hata
						President and Chief Executive Officer